BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28034371)

  • 1. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
    Joura EA; Pils S
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C; Bogers JJ; Verhelst R; Rees H
    Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M
    Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
    Pitisuttithum P; Velicer C; Luxembourg A
    Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From the monovalent to the nine-valent HPV vaccine.
    Pils S; Joura EA
    Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing an HPV vaccine to prevent cervical cancer and genital warts.
    Bryan JT
    Vaccine; 2007 Apr; 25(16):3001-6. PubMed ID: 17289220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M; Musacchio N
    Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
    Luxembourg A; Moeller E
    Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
    van Bergen JEAM
    Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL
    Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.